Tiotropium
- Generic Name
- Tiotropium
- Brand Names
- Inspiolto Respimat, Spiriva, Spiriva Respimat, Stiolto
- Drug Type
- Small Molecule
- Chemical Formula
- C19H22NO4S2
- CAS Number
- 186691-13-4
- Unique Ingredient Identifier
- 0EB439235F
- Background
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma. Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.
Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than ipratropium.
Tiotropium was granted FDA approval on 30 January 2004.
- Indication
Tiotropium powder for inhalation is indicated for the maintenance of bronchospasm in COPD and to prevent exacerbations of COPD. A combination tiotropium and olodaterol metered inhalation spray is indicated for maintenance of COPD. A tiotropium inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 12 or more years old. A tiotropium metered inhalation spray is indicated for the maintenance of bronchospasm in COPD, to prevent exacerbations of COPD, and to treat asthma in patients 6 or more years old.
- Associated Conditions
- Asthma, Bronchitis, Bronchoconstriction, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Emphysema, Exacerbation of COPD
- Associated Therapies
- -
A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.
- Conditions
- First Posted Date
- 2006-01-11
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 653
- Registration Number
- NCT00274560
- Locations
- 🇺🇸
Temple University School of Medicine, Philadelphia, Pennsylvania, United States
🇬🇷University Hospital of Ioannina, Ioannina, Greece
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Comparison of Tiotropium and Ipratropium in a Double-Blind, Double-dummy, Efficacy and Safety Study in Adults With COPD
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 141
- Registration Number
- NCT00274040
- Locations
- 🇰🇷
Chung-ang University Hospital, Seoul, Korea, Republic of
🇰🇷Kangnam St. Mary's Hospital, Seoul, Korea, Republic of
🇰🇷Jeonnam National University Hospital, Kwangju, Korea, Republic of
Measure of the Long Term Influence of SPIRIVA® in Acute Respiratory Disorders
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1000
- Registration Number
- NCT00274014
- Locations
- 🇫🇷
Clinique Saint Sauveur, Angers, France
🇫🇷Hôpital Tenon, Paris cedex 20, France
🇫🇷Hôpital Charles Nicolle, Rouen cedex, France
SPIRIVA in Ususal Care
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 395
- Registration Number
- NCT00274079
- Locations
- 🇬🇧
Coatbridge Health Centre, Coatbridge, United Kingdom
🇬🇧St Chads Surgery, Radstock, United Kingdom
🇬🇧Foresterhill Healthcentre, Aberdeen, United Kingdom
Effects of a 9-months Treatment of SPIRIVA on Health Related Quality of Life in Patients With COPD
- Conditions
- First Posted Date
- 2006-01-10
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 555
- Registration Number
- NCT00274053
- Locations
- 🇫🇷
CH Laennec, Creil, France
🇫🇷Hôpital Pitié Salpétrière, Paris, France
🇫🇷Hôpital Privé Antony, Antony, France
Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in COPD
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 131
- Registration Number
- NCT00239447
- Locations
- 🇺🇸
National Jewish Medical and Research Center, Denver, Colorado, United States
🇺🇸Division of Pulmonary and Critical Care Medicine, Little Rock, Arkansas, United States
🇺🇸LSU MC-Sheveport, Shreveport, Louisiana, United States
Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 107
- Registration Number
- NCT00239499
- Locations
- 🇿🇦
Boehringer Ingelheim Investigational Site, Welkom, South Africa
🇿🇦Tijger Trial Centre, Bellville, South Africa
🇿🇦Durban Lung Centre, Durban, South Africa
Efficacy and Safety (Including 24-hour Holter Monitoring) of Tiotropium Inhalation Capsules in Patients With COPD
- Conditions
- First Posted Date
- 2005-10-17
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 196
- Registration Number
- NCT00239460
- Locations
- 🇺🇸
Attn: William C. Bailey, M.D., Birmingham, Alabama, United States
🇺🇸Boehringer Ingelheim Investigational Site, Houston, Texas, United States
🇺🇸The Oregon Clinic, Portland, Oregon, United States
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients
- Conditions
- First Posted Date
- 2005-09-05
- Last Posted Date
- 2014-05-20
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5993
- Registration Number
- NCT00144339
- Locations
- 🇺🇸
205.235.3781 Boehringer Ingelheim Investigational Site, San Diego, California, United States
🇺🇸205.235.3782 Boehringer Ingelheim Investigational Site, Fredericksburg, Virginia, United States
🇺🇸205.235.3744 Boehringer Ingelheim Investigational Site, Danville, Virginia, United States
High Dose Trial in COPD
- Conditions
- First Posted Date
- 2005-08-10
- Last Posted Date
- 2013-10-29
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 78
- Registration Number
- NCT00128440
- Locations
- 🇺🇸
Boehringer Ingelheim Investigational Site, Tacoma, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.